Long acting GLP-1 receptor agonist (injectable)
Semaglutide 16 mg injection once weekly
SEMA_SC_16MG_QW
Related
- All doses pooled: Semaglutide injection
- Semaglutide 1.0 mg subcutaneous once weekly
- Semaglutide maximum tolerated dose injection once weekly
- Semaglutide 2.4 mg subcutaneous once weekly
- Semaglutide 0.5 mg subcutaneous once weekly
- Semaglutide 0.5 mg injection
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.4 mg injection once daily
- Semaglutide 0.1 mg injection once daily
- Semaglutide 0.2 mg injection once daily
- Semaglutide 0.25 mg injection
- Semaglutide 2.0 mg subcutaneous once weekly
- Semaglutide 1.5 mg injection once weekly
- Semaglutide 8 mg injection once weekly
- Semaglutide 0.1072 mg injection
- Semaglutide 1.7 mg injection once weekly
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.05 mg injection once daily
- Semaglutide 0.3 mg injection once daily
- Semaglutide flexible dose injection once weekly
- Semaglutide 2.4 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.83 (-1.36 to -0.31) | 0.89 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -10.60 (-13.47 to -7.54) | 0.97 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -10.36 (-14.67 to -5.94) | 0.97 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.21 (0.00 to 5.65) | 0.74 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.31 (0.03 to 1.73) | 0.79 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 8.26 (2.25 to 35.62) | 0.11 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.37 (2.04 to 9.44) | 0.30 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.00 (2.05 to 12.46) | 0.30 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.21 (0.94 to 5.13) | 0.36 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 9.72 (2.96 to 37.98) | 0.05 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 5.65 (1.05 to 39.00) | 0.24 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 4.07 (0.47 to 43.82) | 0.23 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.43 (0.03 to 4.38) | 0.62 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 4.70 (0.17 to 155) | 0.23 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.25 (0.00 to 7.83) | 0.65 |